Study on the glucose-lowering effect and metabolic benefit of SGLT2 inhibitors

Prospective observational study on metabolic changes induced by SGLT2 inhibitors or insulin treatment in a single-center, two-arm, open-label design - prospective observational study on metabolic changes induced by SGLT2 inhibitors or insulin treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052955

Enrollment

Registered

2023-11-30

Start date

2020-08-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria comprised a diagnosis of type 2 diabetes mellitus with HbA1c 6.5% or more, age between 20 and 79 years, a stable antidiabetic regimen with insulin for at least 8 weeks prior to the study, and no prior use of SGLT2 inhibitors.

Exclusion criteria

Exclusion criteria: Exclusion criteria encompassed pregnant or breastfeeding women, patients with malignant disease, severe infections (including urinary tract infections), severe trauma, or recent surgery.

Design outcomes

Primary

Measure	Time frame
Changes in the levels of HbA1c.	—

Secondary

Measure	Time frame
Changes in the levels of glycated albumin, fasting blood glucose, and urinary albumin/creatinine ratio.	—

Countries

Japan

Contacts

Public ContactMoeko Sakamoto

Department of Internal Medicine, Kurume University School of Medicine Division of Endocrinology and Metabolism

matsumoto_moeko@kurume-u.ac.jp0942-31-7563

Outcome results